Lv11
38 积分 2024-10-29 加入
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study
12小时前
已关闭
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
12小时前
已完结
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
18天前
已完结
MM-711: Safety Outcomes Following Frontline Daratumumab-Based Therapy in Multiple Myeloma: A Systematic Reviewand Meta-Analysis
27天前
已关闭
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
28天前
已完结
Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma
28天前
已完结
Preclinical Development and Validation of ASP5354: A Near-Infrared Fluorescent Agent for Intraoperative Ureter Visualization
2个月前
已完结
What Is the Definition of Cure for Aplastic Anemia?
3个月前
已完结
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends
4个月前
已完结
Guidelines for determination of the number of prior lines of therapy in multiple myeloma
9个月前
已完结
皖公网安备34019202002308
